You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Biologic agents for giant cell arteritis: treat to target’ by Moiseev et al
Free
  1. Richard Conway1,2,
  2. Eamonn S Molloy1
  1. 1Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital, Dublin Academic Medical Centre, Elm Park, Dublin 4, Ireland
  2. 2CARD Newman Research Fellow, University College Dublin, Belfield, Dublin 4, Ireland
  1. Correspondence to Dr Richard Conway, Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital, Dublin Academic Medical Centre, Elm Park, Dublin 4, Ireland; drrichardconway{at}gmail.com

https://doi.org/10.1136/annrheumdis-2016-210082

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Moiseev et al for their interest in our study of ustekinumab in giant cell arteritis (GCA).1 ,2 Our pilot study reported promising initial results from the use of ustekinumab in GCA.1

    GCA is a potentially devastating disease with cranial ischaemic complications such as blindness and stroke occurring in 20%–25% of patients.3 While corticosteroids are effective in reducing the risk of cranial ischaemic complications, they do not fully extinguish the vascular inflammation in patients with GCA4–6 with consequent risk of disease relapse and longer-term consequences such as …

    View Full Text

    Linked Articles